(ADAG) –
-
Adagene Inc (ADAG) PT Raised to $5 at Morgan Stanley
-
Form 6-K Adagene Inc. For: Mar 29
-
Form 424B5 Adagene Inc.
-
Form 20-F Adagene Inc. For: Dec 31
-
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
-
Form 6-K Adagene Inc. For: Mar 29
-
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
-
Form SC 13D/A Adagene Inc. Filed by: Luo Peter
-
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
-
Form SC 13G/A Adagene Inc. Filed by: FMR LLC
-
Form 6-K Adagene Inc. For: Feb 09
-
Adagene (ADAG) Announces Progress and Expansion of Clinical Collaboration Program for ADG126 in Combination with KEYTRUDA
-
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further
-
Form SC 13G Adagene Inc. Filed by: Huang James
-
Adagene Inc. (ADAG) Presents Interim Results Reinforcing Best-in-Class Profile of ADG126
-
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colo
-
Form 6-K Adagene Inc. For: Jan 16
-
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
-
Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors
-
Adagene Inc. (ADAG) Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126
-
Form 6-K Adagene Inc. For: Nov 03
-
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
-
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
-
Form 6-K Adagene Inc. For: Sep 29
-
Adagene to Present at Investor and Scientific Conferences in September
-
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
-
Form 6-K Adagene Inc. For: Aug 31
-
Form 6-K Adagene Inc. For: Jul 07
-
Adagene Inc. (ADAG) Reaches $3M Milestone in Collaboration with Exelixis
-
Form 6-K Adagene Inc. For: May 04
-
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate
-
Form 6-K Adagene Inc. For: Apr 28
-
Form 20-F Adagene Inc. For: Dec 31
-
Adagene Inc. (ADAG) Announces Board Changes
-
Adagene Announces Updates to its Board of Directors
-
Adagene Announces Updates to its Board of Directors
-
Form 6-K Adagene Inc. For: Apr 18
-
Adagene (ADAG) Presents Clinical Data for Anti-CTLA-4 SAFEbody ADG126
-
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
-
Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors
-
Form 6-K Adagene Inc. For: Mar 28
-
Adagene (ADAG) Reports FY22, Provides Corporate Update
-
Adagene (ADAG) Reports FY22, Provides Corporate Update
-
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
-
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
-
Adagene Inc. (ADAG) Appoints Aurélien Marabelle to its Board
-
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
-
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
Back to ADAG Stock Lookup
